Section 05 / the IV ledger
NAD IV therapy: what the research shows about injectable and infused NAD+
The injectable route has the weakest controlled evidence of any NAD+ delivery method: rapid plasma clearance, infusion-related discomfort if run fast, and a documented compounded-quality recall.
The short version on IV NAD+
NAD IV therapy means dripping NAD+ straight into a vein, usually at a wellness clinic. It is not FDA-approved — it is a compounded preparation (mixed by a pharmacy rather than manufactured as an approved drug), and the controlled evidence behind it is the thinnest of any route. Studies show infused NAD+ leaves the blood within a couple of hours, that running the drip fast provokes chest and abdominal discomfort, and that one compounded product was recalled for contamination. This page lays out what the research actually found, so the claims around the IV drip can be checked against the data rather than the marketing.
What an NAD+ injection is
An NAD+ injection or infusion delivers NAD+ intravenously, or by subcutaneous or intramuscular injection, in wellness settings — bypassing the gut entirely, which is the route's whole pitch given how poorly NAD+ is absorbed by mouth. The catch is what happens once it is in. It is a compounded, FDA-unapproved preparation, infused NAD+ is rapidly cleared from plasma, and the controlled evidence is limited [8]. Unlike an approved medicine, a compounded injectable has no standardized label, no approved dose, and quality that depends entirely on the compounding source.
What the infusion pharmacokinetics show
The most informative human data come from a pilot study that infused 750 mg of NAD+ over six hours in healthy men and tracked the plasma and urine NAD+ metabolome [8]. The finding is striking and underdiscussed in marketing: plasma NAD+ itself stayed undetectable for roughly the first two hours and only rose in the final hours, while the dose showed up as elevated urinary methylated nicotinamide metabolites — meaning the infused NAD+ was extensively metabolized extracellularly rather than circulating as intact NAD+ [8]. The study also noted mild infusion-related symptoms, chest tightness and abdominal discomfort, when the infusion rate was higher [8]. In plain terms: pushing NAD+ into a vein does not produce a clean, durable plasma pool of NAD+, and going faster trades comfort for speed.
Tolerability: IV NAD+ versus IV NR
A 2026 real-world retrospective pilot compared the two infusions head to head and sharpened the tolerability picture. IV NAD+ at 500 mg was associated with moderate-to-severe gastrointestinal symptoms, elevated heart rate, and chest pressure, requiring a mean infusion time of about 97 minutes to stay tolerable; IV NR at 500 mg caused only mild tingling and took roughly 37 minutes on average [15]. All symptoms resolved on completion, with no serious adverse events in either arm [15]. The takeaway is that the discomfort is real and rate-dependent, which is exactly why studied protocols are slow infusions rather than quick shots.
The compounded-quality risk on the record
The single hardest safety fact about IV NAD+ is a regulatory one: a compounded injectable NAD+ product was subject to an FDA Class I recall — the most serious category, reserved for products that could cause serious harm or death — over elevated bacterial endotoxin. Compounded injectables are not manufactured under the same controls as approved drugs, and NAD+ preparations are hygroscopic and degrade with heat and moisture, so reconstituted injectable NAD+ must be kept cold and protected from light. This is the documented quality risk that distinguishes an unapproved compounded wellness therapy from an approved medicine. It is a property of the product class, not a claim about any specific clinic.
The historical and contemporary clinical narrative
IV NAD+ has a long anecdotal history that is worth seeing in proper context. A narrative review documents its use for addiction going back to a 1961 case series of more than 100 patients given 500-1000 mg IV NAD+ daily for four days then maintenance, with reported reduction of cravings and withdrawal symptoms, and a contemporary 750 mg protocol reported without adverse effects at an appropriate infusion rate [9]. Crucially, the same review states plainly that IV NAD+ remains unapproved by the FDA and calls for rigorous randomized controlled trials [9]. That is the honest status of the addiction narrative: historically suggestive, contemporarily under-tested, and explicitly not approved.
Does NAD IV actually work?
Controlled evidence for IV NAD+ is the weakest of all routes. A six-hour infusion pilot showed plasma NAD+ stayed undetectable for the first ~2 hours then rose, with measurable metabolome changes [8]; most clinical use rests on pilot and retrospective data, not randomized trials [9][15].
Is an NAD+ shot worth it?
The published evidence does not let anyone answer that as a value judgment. What the literature shows is limited controlled data [8], rapid plasma clearance of infused NAD+ [8], infusion-related discomfort if run fast [15], and a documented compounded-product contamination recall.
When should you inject NAD+?
Studied IV protocols are slow infusions — for example 750 mg over six hours [8] — rather than rapid shots, because faster rates provoke chest and abdominal symptoms [8][15]. No approved schedule exists; the literature describes infusion rate, not a recommended timing for use.